Arcinova Appoints Christian Dowdeswell as New Managing Director
Former Vice President and Global Head of Commercial Development of Lonza’s small molecules custom manufacturing business to head up Arcinova, Quotient Sciences' CRDMO.
Arcinova, a Quotient Sciences company, and UK-based Contract Research Development and Manufacturing Organisation (CRDMO), has announced the appointment of Christian Dowdeswell as new Managing Director.
Taking the reins from co-founder and Managing Director, Paul Ryan, who recently announced his retirement, Christian joins the firm at a busy time for the business which has recently relaunched with a refreshed brand identity and a renewed focus on delivering integrated drug substance and early drug product services to global biotech and pharmaceutical partners.
Over the past 3–4 years, under Quotient Sciences, the Arcinova facility in Alnwick has received £6.3 million of investment to establish a world-class, 1,500 square-meter GMP manufacturing suite. This state-of-the-art facility now houses 14 GMP manufacturing streams, enabling the production of drug substance from small-scale PR&D batches to multi-kilo quantities, supporting clients from early development through to Proof of Concept.
More recently, they have enhanced their aseptic capabilities to ensure full compliance with the latest Annex 1 requirements, further strengthening their ability to support complex and high-quality manufacturing needs.
Commenting on his appointment, Christian said: “Arcinova has an outstanding reputation for innovation, agility, and scientific excellence—qualities our clients depend on. Paul has built a strong foundation for success, and I’m committed to building on that momentum, driving growth while keeping our customers at the heart of everything we do.”
Bringing over 25 years of sector experience to his role, Christian joins Arcinova from consulting and advisory positions with companies including Nanoform and Pangaea Life Sciences. Prior to this, he was Chief Business Officer Drug Substances at global life sciences company Siegfried AG, and held various senior positions with Lonza, most recently as Vice President and Global Head of Commercial Development of Lonza’s small molecules custom manufacturing business.
Thierry Van Nieuwenhove, CEO of Quotient Sciences, commented: “Christian is a welcome addition to the team and joins Arcinova at an exciting time for the business. He brings a wealth of experience and knowledge of the global CDMO market to the role. Christian’s leadership will be instrumental as Arcinova continues to grow and deliver client service excellence, as we help our customers accelerate the development of new medicines.”
